WO2016022549A1 - Remote loading of sparingly water-soluble drugs into lipid vesicles - Google Patents
Remote loading of sparingly water-soluble drugs into lipid vesicles Download PDFInfo
- Publication number
- WO2016022549A1 WO2016022549A1 PCT/US2015/043594 US2015043594W WO2016022549A1 WO 2016022549 A1 WO2016022549 A1 WO 2016022549A1 US 2015043594 W US2015043594 W US 2015043594W WO 2016022549 A1 WO2016022549 A1 WO 2016022549A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- liposomes
- liposome
- loading
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- compositions include the active therapeutic agent encapsulated within the aqueous interior of a liposome vesicle.
- Liposomes are vesicle structures usually composed of a bilayer membrane of amphipathic molecules such as, phospholipids, entrapping an aqueous core.
- the diameters and morphology of various types of liposomes are illustrated in FIG. 1.
- Drugs are either encapsulated in the aqueous core or interdigitated in the bilayer membrane. Drugs interdigitated in the membrane transfer out of the liposome when it is diluted into the body.
- drugs that are encapsulated in the aqueous core or held in complexes in the aqueous core are retained substantially longer than drugs in the bilayer.
- the use of liposomes with drugs encapsulated in the aqueous core for drug delivery is well established (D.
- a variety of loading methods for encapsulating functional compounds, particularly drugs, in liposomes is available.
- Hydrophilic compounds for example can be encapsulated in liposomes by hydrating a mixture of the functional compounds and vesicle-forming lipids. This technique is called passive loading.
- the functional compound is encapsulated in the liposome as the nanoparticle is formed.
- the available lipid vesicle (liposome) production procedures are satisfactory for most applications where water-soluble drugs are encapsulated (G.
- the final functional-compound-to-lipid ratio as well as the encapsulation efficiency are generally low.
- the concentration of drug in the liposome equals that of the surrounding fluid and drug not entrapped in the internal aqueous medium is washed away after encapsulation.
- hydrophilic or amphiphilic compounds can be loaded into preformed liposomes using transmembrane pH- or ion-gradients (D. Zucker et al, Journal of Controlled Release (2009) 139:73-80). This technique is called active or remote loading. Compounds amenable to active loading should be able to change from an uncharged form, which can diffuse across the liposomal membrane, to a charged form that is not capable thereof.
- the functional compound is loaded by adding it to a suspension of liposomes prepared to have a lower outside/higher inside pH- or ion-gradient.
- a high functional-compound-to-lipid mass ratio and a high loading efficiency (up to 100 %) can be achieved.
- Examples are active loading of anticancer drugs doxorubicin, daunorubicin, and vincristine (P.R. Cullis et al, Biochimica et Biophysica Acta, (1997) 1331 : 187-21 1, and references therein).
- Hydrophobic drugs are only considered capable of loading into liposomes through membrane intercalation via some passive loading/assembly mechanism.
- Wasan et al. states "Agents that have hydrophobic attributes can intercalate into the lipid bilayer and this can be achieved by adding the agent to the preformed liposomes.” in a description of the use of micelles to transfer sparingly soluble agents to a liposome bilayer (US 2009/0028931).
- Remote loading of a sparingly soluble drug into a liposome under conditions where the drug is above its solubility limit and is in the form of a precipitate is an unexpected event. D.
- FIG. 1 illustrates the diameters and morphology of various types of liposomes.
- FIG. 2 Liposome formulations composed of HSPC/Chol/Peg-DSPE containing either sodium sulfate (light shade) or ammonium sulfate (dark shade) were incubated with carfilzomib at two input drug-to-lipid ratios using conditions described below. The liposomes were purified from unencapsulated drug and the amount of encapsulated carfilzomib within the liposomes is shown, expressed as ⁇ g of carfilzomib per ⁇ lipid.
- FIG. 3 is a bar graph showing a trapping agent effect on liposome loading of carfilzomib.
- FIG. 4 is a bar graph showing a method of drug introduction effect on liposome loading of carfilzomib.
- FIG. 5 is a line graph showing carfilzomib loading from precipitate demonstrated by reduction of light scattering at 600 nm.
- FIG. 6 is a HPLC Chromatogram of Carfilzomib before loading into liposomes (upper) and after loading into liposomes from a precipitate and being released from liposomes using a reverse ammonium sulfate gradient back to a precipitate in the
- FIG. 7 is a line graph showing liposome encapsulation efficiency as a function of [DMSO].
- the input drug-to-lipid ratio was 200 ⁇ g/ ⁇ mol.
- FIG. 8 is a line graph showing light scattering of carfilzomib solutionas a function of DMSO concentration. The concentration of carfilzomib was 0.2mg/mL.
- FIG. 9 is a bar graph showing the effect of delay time between the formation of drug precipitate and liposome loading of the precipitate.
- FIG. 10 is a line graph showing the effect of ammonium sulfate trapping agent concentration on liposome drug payload of carfilzomib Loaded from Precipitate.
- FIG. 11 is a line graph showing effect of ammonium sulfate trapping agent concentration on liposome loading efficiency of carfilzomib from precipitate.
- FIG. 12 is a line graph loading insoluble carfilzomib precipitate into liposomes using a triethylammonium sulfate gradient.
- FIG. 13 is a line graph showing the transfer of insoluble carfilzomib precipitate into liposomes by remote loading.
- FIG. 14 is a bar graph showing the comparison of liposome loading of aripiprazole when mixed with liposomes as a SBCD complex (Abilify) or when diluted from a stock DMSO solution directly into liposomes, creating a drug suspension.
- SBCD complex Abilify
- FIG. 15 is a bar graph showing absorbance at 600nm (scattering) of drug solutions (dark bars) and liposome drug mixtures (gray bars). The rectangle indicates the samples where a substantial decrease in scattering was measured upon incubation with liposomes indicating drug loading.
- FIG. 16 is a bar graph showing the loading efficiency of DFX in calcium acetate liposomes.
- FIG. 17 is a plot showing DFX loading capacity in liposomes containing calcium acetate as a trapping agent.
- FIG. 18 is a plot showing DFX loading capacity in liposomes containing different acetate trapping agents.
- FIG. 19A - FIG. 19B are illustrations of the structures of paclitaxel, docetaxel and cabazitaxel and modifications to them that enable the taxanes to be loaded from a precipitate into liposomes containing an ion gradient.
- liposomes for delivery of functional compounds, it is generally desirable to load the liposomes to high concentration, resulting in a high functional-compound-lipid mass ratio, since this reduces the amount of liposomes to be administered per treatment to attain the required therapeutic effect, all the more since several lipids used in liposomes have a dose-limiting toxicity by themselves.
- the loading percentage is also of importance for cost efficiency, since poor loading results in a great loss of the active compound.
- the invention provides a liposome comprising a liposomal lipid membrane encapsulating an internal aqueous medium.
- the internal aqueous medium comprises an aqueous solution of a complex between a trapping agent and a sparingly water-soluble therapeutic agent.
- the invention provides pharmaceutical formulations comprising a liposome of the invention.
- the formulations include the liposome and a pharmaceutically acceptable diluent or excipient.
- the pharmaceutical formulation is in a unit dosage format, providing a unit dosage of the therapeutic agent encapsulated in the liposome.
- the invention provides methods of making the liposomes of the invention.
- a method of remotely loading a liposome with an agent that is sparingly water-soluble comprises: a) incubating an aqueous mixture comprising: (i) a liposome suspension having a proton and/or ion gradient that exists across the liposomal membrane; (ii) with an aqueous suspension of a sparingly soluble drug (iii) wherein the drug suspension is made by completely dissolving the drug in an aprotic solvent or polyol and diluting it into the aqueous solution beyond the point of drug solubility where a precipitate is formed, wherein incubating the combined liposome drug precipitate mixture for a period of time results in the drug accumulating within the liposome interior in response to the proton/ion gradient.
- the mixture used to load the liposome with the agent is prepared such that a proton- and/or ion-gradient exists across the liposomal membrane between the internal aqueous membrane and the external aqueous medium.
- the incubating can be for any useful period but is preferably for a period of time sufficient to cause at least part of the insoluble drug precipitate to accumulate in the internal aqueous medium under the influence of the proton and/or ion gradient.
- liposomes for delivery of functional compounds, it is generally desirable to load the liposomes to high concentration, resulting in a high agent-lipid mass ratio, since this reduces the amount of liposomes to be administered per treatment to attain the required therapeutic effect of the agent, all the more since several lipids used in liposomes have a dose-limiting toxicity by themselves.
- the loading percentage is also of importance for cost efficiency, since poor loading results in an increase loss of agent during the loading of the agent into the liposome.
- the present invention provides liposomes encapsulating agents, e.g., sparingly water- soluble, methods of making such liposomes, formulations containing such liposomes and methods of making the liposomes and formulations of the invention.
- the invention provides a liposome having a membrane encapsulating an aqueous compartment.
- the liposome is prepared such that a proton- and/or ion-gradient exists across the liposomal membrane between the internal aqueous
- the agent is dissolved in an aprotic solvent at a concentration that when diluted in the liposome suspension its solubility in the suspension is exceeded and the agent forms a precipitate.
- a portion of the agent precipitate is loaded into the liposome aqueous compartment using a proton- and/or ion-gradient exists across the liposomal membrane between the internal aqueous compartment and the external aqueous medium.
- essentially the entire amount of the insoluble agent precipitate is loaded into the aqueous compartment of the liposome.
- at least about 95%, at least about 90%, at least about 85%, at least about 80% or at least about 70% of the insoluble drug precipitate is loaded into the aqueous compartment of the liposome.
- liposome is used herein in accordance with its usual meaning, referring to microscopic lipid vesicles composed of a bilayer of phospholipids or any similar amphipathic lipids encapsulating an internal aqueous medium.
- the liposomes of the present invention can be unilamellar vesicles such as small unilamellar vesicles (SUVs) and large unilamellar vesicles (LUVs), and multilamellar vesicles (MLV), typically varying in size from 30 nm to 200 nm.
- SUVs small unilamellar vesicles
- LUVs large unilamellar vesicles
- MLV multilamellar vesicles
- liposomal membrane refers to the bilayer of phospholipids separating the internal aqueous medium from the external aqueous medium.
- Exemplary liposomal membranes useful in the current invention may be formed from a variety of vesicle- forming lipids, typically including dialiphatic chain lipids, such as phospholipids, diglycerides, dialiphatic glycolipids, single lipids such as sphingomyelin and glycosphingolipid, cholesterol and derivates thereof, and combinations thereof.
- dialiphatic chain lipids such as phospholipids, diglycerides, dialiphatic glycolipids, single lipids such as sphingomyelin and glycosphingolipid, cholesterol and derivates thereof, and combinations thereof.
- phospholipids are amphiphilic agents having hydrophobic groups formed of long- chain alkyl chains, and a hydrophilic group containing a phosphate moiety.
- the group of phospholipids includes phosphatidic acid, phosphatidyl glycerols, phosphatidylcholines, phosphatidylethanolamines, phosphatidylinositols, phosphatidylserines, and mixtures thereof.
- the phospholipids are chosen from l,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), dimyristoyl-phosphatidylcholine (DMPC), hydrogenated soy phosphatidylcholine (HSPC), soy phosphatidylcholine (SPC), dimyristoylphosphatidylglycerol (DMPG), disrearoylphosphatidylglycerol (DSPG), 1 -palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), l,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC)distearoyl phosphatidylcholine (DSPC), egg yolk phosphatidylcholine (EYPC) or hydrogenated egg yolk
- HEPC phosphatidylcholine
- SML sterol modified lipids
- cationic lipids cationic lipids and inverse- zwitterlipids.
- Liposomal membranes according to the present invention may further comprise ionophores like nigericin and A23187.
- an exemplary liposomal phase transition temperature is between -25°C and 100°C, e.g., between 4°C and 65°C.
- the phase transition temperature is the temperature required to induce a change in the physical state of the lipids constituting the liposome, from the ordered gel phase, where the hydrocarbon chains are fully extended and closely packed, to the disordered liquid crystalline phase, where the hydrocarbon chains are randomly oriented and fluid.
- Above the phase transition temperature of the liposome the permeability of the liposomal membrane increases.
- a liposome with a transition temperature between the starting and ending temperature of the environment it is exposed to provides a means to release the sparingly water-soluble agent when the liposome passes through its transition temperature.
- the process temperature for the active-loading technique typically is above the liposomal phase transition temperature to facilitate the active-loading process.
- phase transition temperatures of liposomes can, among other parameters, be influenced by the choice of phospholipids and by the addition of steroids like cholesterol, lanosterol, cholestanol, stigmasterol, ergosterol, and the like.
- the liposomes comprise one or more components selected from different phospholipids and cholesterol in several molar ratios in order to modify the transition, the required process temperature and the liposome stability in plasma. Less cholesterol in the mixture will result in less stable liposomes in plasma.
- An exemplary phospholipid composition of use in the invention comprises between about 10 and about 50 mol% of steroids, preferably cholesterol.
- liposomes can be prepared by any of the techniques now known or subsequently developed for preparing liposomes.
- the liposomes can be formed by the conventional technique for preparing multilamellar lipid vesicles (MLVs), that is, by depositing one or more selected lipids on the inside walls of a suitable vessel by dissolving the lipids in chloroform and then evaporating the chloroform, and by then adding the aqueous solution which is to be encapsulated to the vessel, allowing the aqueous solution to hydrate the lipid, and swirling or vortexing the resulting lipid suspension. This process engenders a mixture including the desired liposomes.
- MLVs multilamellar lipid vesicles
- lipid-containing particles can be in the form of steroidal lipid vesicles, stable plurilamellar lipid vesicles (SPLVs), monophasic vesicles (MPVs), or lipid matrix carriers (LMCs).
- SPLVs stable plurilamellar lipid vesicles
- MPVs monophasic vesicles
- LMCs lipid matrix carriers
- the liposomes can be subjected to multiple (five or more) freeze-thaw cycles to enhance their trapped volumes and trapping efficiencies and to provide a more uniform interlamellar distribution of solute.
- the liposomes are optionally sized to achieve a desired size range and relatively narrow distribution of liposome sizes.
- a size range of about 20-200 nanometers allows the liposome suspension to be sterilized by filtration through a conventional filter, typically a 0.22 or 0.4 micron filter.
- the filter sterilization method can be carried out on a high through-put basis if the liposomes have been sized down to about 20- 200 nanometers.
- Homogenization is another method which relies on shearing energy to fragment large liposomes into smaller ones.
- multilamellar vesicles are recirculated through a standard emulsion homogenizer until selected liposome sizes, typically between about 50 and 500 nanometers, are observed.
- the particle size distribution can be monitored by conventional laser-beam particle size determination.
- Extrusion of liposome through a small-pore polycarbonate membrane or an asymmetric ceramic membrane is also an effective method for reducing liposome sizes to a relatively well-defined size distribution.
- the suspension is cycled through the membrane one or more times until the desired liposome size distribution is achieved.
- the liposomes may be extruded through successively smaller-pore membranes, to achieve a gradual reduction in liposome size.
- controlled size liposomes can be prepared using microfluidic techniques werein the lipid in an organic solvent such as ethanol or ethanol-aprotic solvent mixtures is rapidly mixed with the aqueous medium, so that the organic solvent/ water ratio is less than 30%, in a microchannel with dimensions less than 300 microns and preferable less than 150 microns in wide and 50 microns in height.
- the organic solvent is then removed from the liposomes by dialysis.
- Other useful sizing methods such as sonication, solvent vaporization or reverse phase evaporation are known to those of skill in the art.
- Exemplary liposomes for use in various embodiments of the invention have a size of from about 30 nanometers to about 40 microns.
- the internal aqueous medium typically is the original medium in which the liposomes were prepared and which initially becomes encapsulated upon formation of the liposome.
- freshly prepared liposomes encapsulating the original aqueous medium can be used directly for active loading.
- the liposomes, after preparation are dehydrated, e.g. for storage.
- the present process may involve addition of the dehydrated liposomes directly to the external aqueous medium used to create the transmembrane gradients.
- Liposomes are optionally dehydrated under reduced pressure using standard freeze-drying equipment or equivalent apparatus.
- the liposomes and their surrounding medium are frozen in liquid nitrogen before being dehydrated and placed under reduced pressure.
- one or more protective sugars are typically employed to interact with the lipid vesicle membranes and keep them intact as the water in the system is removed.
- a variety of sugars can be used, including such sugars as trehalose, maltose, sucrose, glucose, lactose, and dextran.
- disaccharide sugars have been found to work better than monosaccharide sugars, with the disaccharide sugars trehalose and sucrose being most effective.
- Other more complicated sugars can also be used.
- aminoglycosides including streptomycin and dihydrostreptomycin, have been found to protect liposomes during dehydration.
- one or more sugars are included as part of either the internal or external media of the lipid vesicles. Most preferably, the sugars are included in both the internal and external media so that they can interact with both the inside and outside surfaces of the liposomes' membranes.
- Inclusion in the internal medium is accomplished by adding the sugar or sugars to the buffer which becomes encapsulated in the lipid vesicles during the liposome formation process.
- the external medium used during the active loading process should also preferably include one or more of the protective sugars
- polyethylene glycol (PEG)-lipid conjugates have been used extensively to improve circulation times for liposome- encapsulated functional compounds, to avoid or reduce premature leakage of the functional compound from the liposomal composition and to avoid detection of liposomes by the body's immune system.
- Attachment of PEG-derived lipids onto liposomes is called PEGylation.
- the liposomes are PEGylated liposomes. PEGylation can be accomplished by incubating a reactive derivative of PEG with the target liposomes.
- Suitable PEG-derived lipids include conjugates of DSPE-PEG, functionalized with one of carboxylic acids, glutathione (GSH), maleimides (MAL), 3-(2-pyridyldithio) propionic acid (PDP), cyanur, azides, amines, biotin or folate, in which the molecular weight of PEG is between 2000 and 5000 g/mol.
- Other suitable PEG-derived lipids are mPEGs conjugated with ceramide, having either C 8 - or entails, in which the molecular weight of mPEG is between 750 and 5000 daltons.
- Still other appropriate ligands are mPEGs or functionalized PEGs conjugated with glycerophospholipds like l,2-dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE), 1,2-dipalmitoyl-sn-glycero- 3-phosphoethanolamine (DPPE), l,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and l,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and the like.
- DMPE 1,2-dipalmitoyl-sn-glycero- 3-phosphoethanolamine
- DOPE 1,2-dipalmitoyl-sn-glycero- 3-phosphoethanolamine
- DOPE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine
- DOPE 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine
- DSPE l,2-
- the liposomes are PEGylated with DSPE-PEG-GSH conjugates (up to 5 mol %) and/or DSPE-mPEG conjugates (wherein the molecular weight of PEG is typically within the range of 750-5000 daltons, e.g. 2000 daltons).
- the phospholipid composition of an exemplary PEGylated lipsome of the invention may comprise up to 5-20 mol % of PEG-lipid conjugates.
- one or more moieties that specifically target the liposome to a particular cell type, tissue or the like are incorporated into the membrane.
- Targeting of liposomes using a variety of targeting moieties e.g., ligands, receptors and monoclonal antibodies has been previously described.
- targeting moieties include hyaluronic acid, anti-ErbB family antibodies and antibody fragments, lipoprotein lipase (LPL), [a]2-macroglobulin ([a]2M), receptor associated protein (RAP), lactoferrin, desmoteplase, tissue- and urokinase-type plasminogen activator (tPA/uPA), plasminogen activator inhibitor (PAI-I), tPA/uPA:PAI-l complexes, melanotransferrin (or P97), thrombospondin 1 and 2, hepatic lipase, factor Vila/tissue-factor pathway inhibitor (TFPI), factor Villa, factor IXa, ⁇ [ ⁇ ]1-40, amyloid-[ ] precursor protein (APP), CI inhibitor, complement C3, apolipoproteinE (apoE), pseudomonas exotoxin A, CRM66, HIV-I Tat protein, rhinovirus, matrix metalloproteinase 9 (M
- Targeting mechanisms generally require that the targeting agents be positioned on the surface of the liposome in such a manner that the target moieties are available for interaction with the target, for example, a cell surface receptor.
- the targeting agents be positioned on the surface of the liposome in such a manner that the target moieties are available for interaction with the target, for example, a cell surface receptor.
- the liposome is manufactured to include a connector portion incorporated into the membrane at the time of forming the membrane.
- An exemplary connector portion has a lipophilic portion which is firmLy embedded and anchored in the membrane.
- An exemplary connector portion also includes a hydrophilic portion which is chemically available on the aqueous surface of the liposome. The hydrophilic portion is selected so that it will be chemically suitable to form a stable chemical bond with the targeting agent, which is added later. Techniques for incorporating a targeting moiety in the liposomal membrane are generally known in the art.
- the present invention provides liposomes encapsulating a a sparingly water-soluble agent.
- the term 'sparingly water-soluble means being insoluble or having a very limited solubility in water, more in particular having an aqueous solubility of less than 2 mg/mL, e.g., less than 1.9 mg/mL, e.g., having an aqueous solubility of less than 1 mg/mL.
- the sparingly water-soluble agent is a therapeutic agent selected from the group of a therapeutic is selected from a group consisting of an amphotericin B compound, an anthracycline compound, a camptothecin compound, a vinca alkaloid, an ellipticine compound, a taxane compound, a wortmannin compound, a geldanamycin compound, a pyrazolopyrimidine compound, a peptide-based compound such as carfilzomib, a steroid compound, a derivative of any of the foregoing, a pro-drug of any of the foregoing, and an analog of any of the foregoing.
- Exemplary small molecule compounds having a water solubility less than about 2 mg/mL include, but are not limited to, amphotericin B, 2'deoxyamphotericin B, carfilzomib, voriconazole, amiodarone, ziprasidone, aripiprazole, imatinib, lapatinib, cyclopamine, oprozomib, CUR-61414, PF-05212384, PF-4691502, toceranib, PF-477736, PF-337210, sunitinib, SU14813, axitinib, AG014699, veliparib, MK-4827, ABT-263, SU1 1274,
- An exemplary therapeutic agent is selected from: an antihistamine ethylenediamine derivative, bromphenifamine, diphenhydramine, an anti-protozoal drug, quinolone, iodoquinol, an amidine compound, pentamidine, an antihelmintic compound, pyrantel, an anti-schistosomal drug, oxaminiquine, an antifungal triazole derivative, fliconazole, itraconazole, ketoconazole, miconazole, an antimicrobial cephalosporin, chelating agents, deferoxamine, deferasirox, deferiprone, FBS0701, cefazolin, cefonicid, cefotaxime, ceftazimide, cefuoxime, an antimicrobial beta-lactam derivative, aztreopam, cefmetazole, cefoxitin, an antimicrobial of erythromycin group, erythromycin, azithromycin,
- clarithromycin oleandomycin, a penicillin compound, benzylpenicillin,
- the compound encapsulated within the liposome can be any sparingly water-soluble amphipathic weak base or amphipathic weak acid.
- the sparingly water-soluble agent is not a pharmaceutical or medicinal agent are also encompassed by the present invention.
- sparingly water-soluble amphipathic weak bases have an octanol-water distribution coefficient (logD) at pH 7 between -2.5 and 7.0 and pKa ⁇ 11, while sparingly water-soluble amphipathic weak acids have a logD at pH 7 between -2.5 and 7.0 and pKa > 3. The pKa is measured in water.
- weak base and weak acid respectively refer to compounds that are only partially protonated or deprotonated in water.
- protonable agents include compounds having an amino group, which can be protonated in acidic media, and compounds which are zwitterionic in neutral media and which can also be protonated in acidic environments.
- deprotonable agents include compounds having a carboxy group, which can be deprotonated in alkaline media, and compounds which are zwitterionic in neutral media and which can also be deprotonated in alkaline
- the term zwitterionic refers to compounds that can simultaneously carry a positive and a negative electrical charge on different atoms.
- amphipathic as used in the foregoing is typically employed to refer to compounds having both lipophilic and hydrophilic moieties. The foregoing implies that aqueous solutions of compounds being weak amphipathic acids or bases simultaneously comprise charged and uncharged forms of said compounds. Only the uncharged forms may be able to cross the liposomal membrane.
- salts of such compounds are included in the scope of the invention. Salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid or base, either neat or in a suitable inert solvent.
- Examples of salts for relative acidic compounds of the invention include sodium, potassium, calcium, ammonium, organic amino, or magnesium salts, or a similar salts.
- acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.
- acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from organic acids like acetic, propionic, isobutyric, maleic, malonic, benzoic, succinic, suberic, fumaric, lactic, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like.
- salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge et al, Journal of Pharmaceutical Science 1977, 66: 1-19).
- Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
- the neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner.
- the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.
- the precipitate of the sparingly water-soluble agent is transferred from the external aqueous medium across the liposomal membrane to the internal aqueous medium by a transmembrane proton- or ion-gradient.
- the term gradient of a particular compound as used herein refers to a discontinuous increase of the concentration of said compound across the liposomal membrane from outside (external aqueous medium) to inside the liposome (internal aqueous medium).
- the liposomes are typically formed in a first liquid, typically aqueous, phase, followed by replacing or diluting said first liquid phase.
- the diluted or new external medium has a different concentration of the charged species or a totally different charged species, thereby establishing the ion- or proton-gradient.
- the replacement of the external medium can be accomplished by various techniques, such as, by passing the lipid vesicle preparation through a gel filtration column, e.g., a Sephadex or Sepharose column, which has been equilibrated with the new medium, or by centrifugation, dialysis, or related techniques.
- a gel filtration column e.g., a Sephadex or Sepharose column
- the efficiency of active-loading into liposomes depends, among other aspects, on the chemical properties of the complex to be loaded and the type and magnitude of the gradient applied.
- a method as defined in any of the foregoing employing a gradient across the liposomal membrane, in which the gradient is chosen from a pH-gradient, a sulfate-, phosphate-, citrate-, or acetate-salt gradient, an EDTA- ion gradient, an ammonium-salt gradient, an alkylated, e.g methyl-, ethyl-, propyl- and amyl, ammonium-salt gradient, a Ca , Cu , Fe , Mg ' Mn , Zn , Na -, K -gradient, with or without using ionophores, or a combination thereof.
- the internal aqueous medium of pre-formed, i.e., unloaded, liposomes comprises a so-called active-loading buffer which contains water and, dependent on the type of gradient employed during active loading, may further comprise a sulfate-, phosphate-, citrate-, or acetate-salt, an ammonium-salt, an alkylated, e.g., methyl-, ethyl-, propyl- and amyl, ammonium-salt, an Ca 2+ , Cu 2+ , Fe +2 , Mg 2+ ' Mn 2+ , Zn 2+ , Na + and/ or K + -salt, an EDTA- ion salt, and optionally a pH-buffer to maintain a pH-gradient.
- active-loading buffer which contains water and, dependent on the type of gradient employed during active loading, may further comprise a sulfate-, phosphate-, citrate-, or acetate-salt,
- the salts may be polymeric such as dextran sulfate, polyethyleneimine, polyamidoamine dendrimers, the 1.5 carboxylate terminal version of polyamidoamines, polyphosphates, low molecular weight heparin, or hyaluronic acid.
- concentration of salts in the internal aqueous medium of unloaded liposomes is between 1 and 1000 mM.
- the external aqueous medium used to establish the transmembrane gradient for active loading, comprises water, the precipitate of the sparingly water-soluble agent(s) to be loaded, and optionally sucrose, saline or some other agent to adjust the osmolarity and/or a chelator like EDTA to aid ionophore activity, more preferably sucrose and/or EDTA.
- the gradient is chosen from an amine or a metal salt of a member selected from a carboxylate, sulfate or phosphate or an acetate.
- transmembrane pH- (lower inside, higher outside pH) or cation acetate-gradients can be used to actively load amphiphilic weak acids.
- Amphipathic weak bases can also be actively loaded into liposomes using an ammonium sulfate- or triethylamine sulfate, triethylamine dextran sulfate or ammonium chloride-gradient.
- Carboxylates of use in the invention include, without limitation, carboxylate, citrate, diethylenetriaminepentaaceetate, melletic acetate, 1,2,3,4-butanetetracarboxylate, benzoate, isophalate, phthalate, 3,4-bis(carboxymethyl)cyclopentanecarboxylate, the carboxylate generation of polyamidoamine dendrimers, benzenetricarboxylates, benzenetetracarboxylates, ascorbate, ascorbate phosphate, glucuronate, and ulosonate.
- Sulfates of use in the invention include, but are not limited to, sulfate, 1,5- naphthalenedisulfonate, dextran sulfate, sulfobutlyether beta cyclodextrin, sucrose octasulfate benzene sulfonate, poly(4-styrenesulfonate) trans resveratrol-trisulfate.
- Phosphates of use in the invention include, but are not limited to, phosphate, ascorbate phosphate, hexametaphosphate, phosphate glasses, polyphosphates, triphosphate, trimetaphosphate, bisphosphonates, ethanehydroxy bisphosphonate, inositol hexaphosphate
- Exemplary salts of use in the invention include a mixture of carboxylate, sulfate or phosphate including but not limited to: 2-carboxybenensulfonate, creatine phosphate, phosphocholine, carnitine phosphate, the carboxyl generation of polyamidoamines.
- Amines of use in the invention include, but are not limited to, monoamines, polyamines, trimethylammonium, triethylammonium, tributyl ammonium,
- dicychohexylammonium protonized forms of morpholine, pyridine, piperidine, pyrrolidine, piperazine, imidazole, tert-butylamine, 2-amino-2-methylpropanol, 2-amino-2-methyl- propandiol, tris-(hydroxyethyl)-aminomethane, diethyl-(2-hydroxyethyl)amine, tris- (hydroxymethyl)-aminomethane tetramethylammonium, tetraethylammonium, N- methylglucamine and tetrabutylammonium, polyethyleneimine, and polyamidoamine dendrimers.
- the full transmembrane potential corresponding to the concentration gradient will either form spontaneously or a permeability enhancing agent, e.g., a proton ionophore can be added to the medium.
- a permeability enhancing agent e.g., a proton ionophore
- the permeability enhancing agent can be removed from the liposome preparation after loading with the complex is complete using chromatography or other techniques.
- the temperature of the medium during active loading is between about - 25°C and about 100°C, e.g., between about 0°C and about 70°C, e.g., between about 4°C and 65°C.
- the encapsulation or loading efficiency defined as encapsulated amount (e.g., as measured in grams of agent / moles of phospholipid or g of drug/g total lipid) of the sparingly water-soluble agent in the internal aqueous phase divided by the initial amount in the external aqueous phase multiplied by 100%, is at least 10 %, preferably at least 50%, at least 90 %.
- the invention provides a method of loading a sparingly water-soluble agent into a liposome.
- An exemplary method comprises, contacting an aqueous suspension of said liposome with said aqueous suspension of said agent under conditions appropriate to encapsulate said sparingly water-soluble agent in said liposome, wherein said liposome has an internal aqueous environment encapsulated by a lipid membrane and said aqueous suspension of said liposome comprises a gradient selected from a proton gradient, an ion gradient and a combination thereof across said membrane, and wherein said conditions are appropriate for said sparingly water-soluble agent to traverse said membrane and concentrate in said internal aqueous environment, thereby forming said pharmaceutical formulation.
- the reaction mixture above is incubated for a selected period of time and the pH gradient, sulfate gradient, phosphate gradient, carboxylate gradient (citrate gradient, acetate gradient), EDTA ion gradient, ammonium salt gradient, alkylated ammonium salt gradient, Ca 2+ , Cu 2+ , Fe +2 , Mg 2+ ' Mn 2+ , Zn 2+ , Na + gradient, K + gradient or a combination thereof, exists across the liposomal membrane during the incubating.
- the pH gradient, sulfate gradient, phosphate gradient, carboxylate gradient (citrate gradient, acetate gradient), EDTA ion gradient, ammonium salt gradient, alkylated ammonium salt gradient, Ca 2+ , Cu 2+ , Fe +2 , Mg 2+ ' Mn 2+ , Zn 2+ , Na + gradient, K + gradient or a combination thereof exists across the liposomal membrane during the incubating.
- the sparingly water-soluble therapeutic agent is not covalently attached to a component of the liposome, nor is it covalently attached to any component of the pH or salt gradient used to form the liposomal preparation of the invention.
- the sparingly water-soluble agent is completely dissolved in an aprotic solvent that is miscible with water.
- the agent solution is added to the aqueous liposome suspension at a concentration that is greater than the solubility of the drug agent in either the liposome suspension or the liposome suspension/aprotic solvent mixture, thus a precipitate is formed.
- Exemplary aprotic solvents include dimethylsulfoxide, dioxane, tetrahydrofuran, dimethylformamide, acetonitrile, dimethylacetamide, sulfolane, gamma butyrolactone, pyrrolidones, l-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, PEG400 and polyethylene glycols.
- the invention describes loading of an insoluble precipitate.
- An exemplary precipitate is conceptualized as some insoluble portion of the agent in suspension.
- the insoluble portion is defined as a portion of the agent that is not solvated as indicated by any of the following: any appearance of cloudiness greater than that of the liposome suspension in the absence of the agent, any degree of increased light scattering at a wavelength where the contents do not absorb light, such at 600 nm greater than the liposome suspension alone, any portion of the drug than can be isolated (pelleted) through centrifugation at a rate below 12,000 RPM for 15 min, any portion of the drug agent than can be isolated by filtration through 0.2 um filter.
- the invention provides a kit containing one or more components of the liposomes or formulations of the invention and instructions on how to combine and use the components and the formulation resulting from the combination.
- the kit includes a the sparingly water-soluble agent in one vessel and a liposome preparation in another vessel.
- An exemplary liposome preparation includes a distribution of salt on the outside and inside of the lipid membrane to establish and/or maintain an ion gradient, such as that described herein.
- the amount of complex and liposome are sufficient to formulate a unit dosage formulation of the complexed agent.
- one vessel includes a liposome or liposome solution, which is used to convert at least part of the contents of a vessel of a sparingly water-soluble therapeutic agent formulation (e.g., of an approved therapeutic agent) into a liquid formulation of the liposome encapsulated therapeutic agent at the point of care for administration to a subject.
- a sparingly water-soluble therapeutic agent formulation e.g., of an approved therapeutic agent
- the contents of the vessels are sufficient to formulate a unit dosage formulation of the therapeutic agent.
- the vessel includes from about 1 mg to about 500 mg of the therapeutic agent, e.g, from about 1 mg to about 200 mg, e.g., from about 5 mg to about 100 mg, e.g., from about 10 mg to about 60 mg.
- the approved therapeutic agent is carfilzomib and it is present in the vessel in an amount of from about 40 mg to about 80 mg, e.g., from about 50 mg to about 70 mg. In an exemplary embodiment, the carfilzomib is present in about 60 mg.
- the invention provides a method of treating a proliferative disorder, e.g., a cancer, in a subject, e.g., a human, the method comprising administering a composition that comprises a pharmaceutical formulation of the invention to a subject in an amount effective to treat the disorder, thereby treating the proliferative disorder.
- a proliferative disorder e.g., a cancer
- a subject e.g., a human
- the method comprising administering a composition that comprises a pharmaceutical formulation of the invention to a subject in an amount effective to treat the disorder, thereby treating the proliferative disorder.
- the pharmaceutical formulation is administered in combination with one or more additional anticancer agent, e.g., chemotherapeutic agent, e.g., a chemotherapeutic agent or combination of chemotherapeutic agents described herein, and radiation.
- additional anticancer agent e.g., chemotherapeutic agent, e.g., a chemotherapeutic agent or combination of chemotherapeutic agents described herein, and radiation.
- the cancer is a cancer described herein.
- the cancer can be a cancer of the bladder (including accelerated and metastatic bladder cancer), breast (e.g., estrogen receptor positive breast cancer; estrogen receptor negative breast cancer; HER- 2 positive breast cancer; HER-2 negative breast cancer; progesterone receptor positive breast cancer; progesterone receptor negative breast cancer; estrogen receptor negative, HER-2 negative and progesterone receptor negative breast cancer (i.e., triple negative breast cancer); inflammatory breast cancer), colon (including colorectal cancer), kidney (e.g., transitional cell carcinoma), liver, lung (including small and non-small cell lung cancer, lung
- adenocarcinoma and squamous cell cancer genitourinary tract
- ovary including fallopian tube and peritoneal cancers
- cervix e.g., prostate, testes, kidney, and ureter
- lymphatic system e.g., rectum, larynx
- pancreas including exocrine pancreatic carcinoma
- esophagus stomach, gall bladder, thyroid
- skin including squamous cell carcinoma
- brain including glioblastoma multiforme
- head and neck e.g., occult primary
- soft tissue e.g., Kaposi's sarcoma (e.g., AIDS related Kaposi's sarcoma), leiomyosarcoma, angiosarcoma, and histiocytoma).
- Kaposi's sarcoma e.g., AIDS related Kaposi's sarcoma
- the cancer is multiple myeloma.
- the pharmaceutical formulation of the invention includes carfilzomib as the sparingly water- soluble therapeutic agent.
- the disclosure features a method of treating a disease or disorder associated with inflammation, e.g., an allergic reaction or an autoimmune disease, in a subject, e.g., a human, the method comprises: administering a composition that comprises a Pharmaceutical formulation of the invention to a subject in an amount effective to treat the disorder, to thereby treat the disease or disorder associated with inflammation.
- a disease or disorder associated with iron overload such as occurs when a patient receives multiple units of blood transfusion such as occurs in thalassemia, sickle anemia, traumatic injury or after a bone marrow transplant.
- the iron overload may be local, such as can occur in endometriosis due to the extravasation of red blood cells into the local tissue where the provoke an inflammatory immune response.
- the disease or disorder associated with inflammation is a disease or disorder described herein.
- the disease or disorder associated with inflammation can be for example, multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, degenerative joint disease, spondouloarthropathies, gouty arthritis, systemic lupus erythematosus, juvenile arthritis, rheumatoid arthritis, osteoarthritis, osteoporosis, diabetes (e.g., insulin dependent diabetes mellitus or juvenile onset diabetes), menstrual cramps, cystic fibrosis, inflammatory bowel disease, irritable bowel syndrome, Crohn's disease, mucous colitis, ulcerative colitis, gastritis, esophagitis, pancreatitis, peritonitis, Alzheimer's disease, shock, ankylosing spondylitis, gastritis, conjunctivitis, pancreatitis (acute or chronic), multiple organ injury syndrome (e.
- Exemplary inflammatory conditions of the skin include, for example, eczema, atopic dermatitis, contact dermatitis, urticaria, scleroderma, psoriasis, and dermatosis with acute inflammatory components.
- the autoimmune disease is an organ- tissue autoimmune diseases (e.g., Raynaud's syndrome), scleroderma, myasthenia gravis, transplant rejection, endotoxin shock, sepsis, psoriasis, eczema, dermatitis, multiple sclerosis, autoimmune thyroiditis, uveitis, systemic lupus erythematosis, Addison's disease, autoimmune polyglandular disease (also known as autoimmune polyglandular syndrome), or Grave's disease.
- organ- tissue autoimmune diseases e.g., Raynaud's syndrome
- scleroderma myasthenia gravis
- transplant rejection transplant rejection
- endotoxin shock sepsis
- psoriasis psoriasis
- eczema dermatitis
- dermatitis e.g., multiple sclerosis
- autoimmune thyroiditis uveitis
- a pharmaceutical formulation of the invention or method described herein may be used to treat or prevent allergies and respiratory conditions, including asthma, bronchitis, pulmonary fibrosis, allergic rhinitis, oxygen toxicity, emphysema, chronic bronchitis, acute respiratory distress syndrome, and any chronic obstructive pulmonary disease (COPD).
- COPD chronic obstructive pulmonary disease
- the pharmaceutical formulation of the invention, particle or composition may be used to treat chronic hepatitis infection, including hepatitis B and hepatitis C.
- the disclosure features a method of treating cardiovascular disease, e.g., heart disease, in a subject, e.g., a human, the method comprising administering a a pharmaceutical formulation of the invention to a subject in an amount effective to treat the disorder, thereby treating the cardiovascular disease.
- cardiovascular disease e.g., heart disease
- cardiovascular disease is a disease or disorder described herein.
- the cardiovascular disease may be cardiomyopathy or myocarditis; such as idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug- induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy.
- cardiomyopathy or myocarditis such as idiopathic cardiomyopathy, metabolic cardiomyopathy, alcoholic cardiomyopathy, drug- induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy.
- atheromatous disorders of the major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries.
- vascular diseases that can be treated or prevented include those related to platelet aggregation, the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems.
- disorders that may be treated with pharmaceutical formulation of the invention, include restenosis, e.g., following coronary intervention, and disorders relating to an abnormal level of high density and low density cholesterol.
- the pharmaceutical formulation of the invention can be administered to a subject undergoing or who has undergone angioplasty.
- the Pharmaceutical formulation of the invention, particle or composition is administered to a subject undergoing or who has undergone angioplasty with a stent placement.
- the pharmaceutical formulation of the invention, particle or composition can be used as a strut of a stent or a coating for a stent.
- the invention provides a method of treating a disease or disorder associated with the kidney, e.g., renal disorders, in a subject, e.g., a human, the method comprises: administering a pharmaceutical formulation of the invention to a subject in an amount effective to treat the disorder, thereby treating the disease or disorder associated with kidney disease.
- the disease or disorder associated with the kidney is a disease or disorder described herein.
- the disease or disorder associated with the kidney can be for example, acute kidney failure, acute nephritic syndrome, analgesic nephropathy, atheroembolic renal disease, chronic kidney failure, chronic nephritis, congenital nephrotic syndrome, end-stage renal disease, good pasture syndrome, interstitial nephritis, kidney damage, kidney infection, kidney injury, kidney stones, lupus nephritis,
- membranoproliferative GN I membranoproliferative GN II
- membranous nephropathy minimal change disease, necrotizing glomerulonephritis, nephroblastoma, nephrocalcinosis, nephrogenic diabetes insipidus, nephrosis (nephrotic syndrome), polycystic kidney disease, post-streptococcal GN, reflux nephropathy, renal artery embolism, renal artery stenosis, renal papillary necrosis, renal tubular acidosis type I, renal tubular acidosis type II, renal underperfusion, renal vein thrombosis.
- the disease or disorder is caused by a microbe or virus.
- infectious agents can be viruses such as HIV, fungi such as aspergillosis, bacteria such as staphylococcus, protist, such as malaria or multicellular infectious agents, such as schistosomyosis.
- an "effective amount” or “an amount effective” refers to an amount of the pharmaceutical formulation of the invention which is effective, upon single or multiple dose administrations to a subject, in treating a cell, or curing, alleviating, relieving or improving a symptom of a disorder.
- An effective amount of the composition may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual.
- An effective amount is also one in which any toxic or detrimental effects of the composition are outweighed by the
- the term "prevent” or “preventing” as used in the context of the administration of an agent to a subject refers to subjecting the subject to a regimen, e.g., the administration of a pharmaceutical formulation of the invention such that the onset of at least one symptom of the disorder is delayed as compared to what would be seen in the absence of the regimen.
- the term "subject” is intended to include human and non-human animals.
- exemplary human subjects include a human patient having a disorder, e.g., a disorder described herein, or a normal subject.
- non-human animals includes all vertebrates, e.g., non-mammals (such as chickens, amphibians, reptiles) and mammals, such as non-human primates, domesticated and/or agriculturally useful animals, e.g., sheep, dog, cat, cow, pig, etc.
- treat or “treating" a subject having a disorder refers to subjecting the subject to a regimen, e.g., the administration of a pharmaceutical formulation of the invention such that at least one symptom of the disorder is cured, healed, alleviated, relieved, altered, remedied, ameliorated, or improved. Treating includes administering an amount effective to alleviate, relieve, alter, remedy, ameliorate, improve or affect the disorder or the symptoms of the disorder. The treatment may inhibit deterioration or worsening of a symptom of a disorder.
- Ammonium sulfate solution was prepared by dissolving ammonium sulfate solid to a final concentration of 250 mM (500 mequivilents of anion/L) no pH adjustment was made to yield a final pH of 5.6.
- Sodium sulfate solution 250mM was prepared by adding 0.35g sodium sulfate to 10 mL deionized water.
- the liposomes were formed by extrusion. Lipids were dissolved in ethanol at a concentration of 500 mM HSPC (591 mg/mL total lipid) at 65 °C and the 9 volumes of the trapping agent solution heated to 65 °C was added to the ethanol/lipid solution also at 65 °C. The mixture was vortexed and transferred to a 10 mL thermostatically controlled (65 °C) Lipex Extruder. The liposomes were formed by extruding 10 times through polycarbonate membranes having 0.1 um pores. After extrusion the liposomes were cooled on ice.
- the transmembrane electrochemical gradient was formed by purification of the liposomes by dialysis in dialysis tubing having a molecular weight cut off of 12,000-14,000.
- the samples are dialyzed against 5 mM HEPES, 10% sucrose pH 6.5 (stirring at 4 °C) at volume that is 100 fold greater than the sample volume.
- the dialysate was changed after 2 h then 4 more times after 12 h each.
- the conductivity of the liposome solution was measured and was indistinguishable from the dialysis medium ⁇ 40 ⁇ 8/ ⁇ .
- the flow rate is 1.0 mL/min
- column temperature is 50 °C
- the retention time of cholesterol is 4.5 min.
- the liposome size is measured by dynamic light scattering.
- Carfilzomib (Selleck Chemicals) was dissolved in DMSO at a concentration of 10 mg/mL.
- the carfilzomib was introduced to the liposomes at a carfilzomib to HSPC ratio of 100 g drug/mol HSPC (drug to total lipid ratio (wt/wt) of 0.12).
- the liposomes were diluted with 50 mM citrate, 10% sucrose pH 4.0 to increase the volume to a point where after addition of the drug the final DMSO concentration is 2%.
- the carfilzomib/DMSO was added to the diluted liposomes, which were mixed at room temperature then transferred to a 65° C bath and swirled every 30 s for the first 3 min and then swirled every 5 min over a total heating time of 30 min. All samples were very cloudy when the drug was added and all became clear (same as liposomes with no drug added) after 15 min. After heating for 30 min all samples were placed on ice for 15 min. The loaded liposomes were vortexed and 100 ⁇ ⁇ ⁇ sample was kept as the "before column" and the rest transferred to microcentrifuge tubes and spun at 10,000 RPM for 5 min.
- the supematants were purified on a Sephadex G25 column collected and analyzed by HPLC.
- the HPLC analysis of carfilzomib was performed on the same system as described for analysis of cholesterol.
- the flow rate is 1.0 mL/min
- column temperature is 30 C
- the retention time of carfilzomib is 12.2 min.
- the lipid concentration is determined by analysis of the cholesterol by HPLC.
- control liposomes containing 250 mM sodium sulfate which have no electrochemical gradient for remote loading resulted in a final drug load of 33.28 ⁇ 0.79 and 29.01 ⁇ 0.79 g drug/mol of HSPC when the drug was added at a ratio of 100 and 200 g drug/mol of HSPC respectively.
- Saturation of the drug loading capacity for sodium sulfate liposomes at a ratio at least 3 fold lower than the ammonium sulfate liposomes indicates that when no electrochemical gradient is present for remote loading the drug partitions into the lipid bilayer but does not form a salt with the interior trapping agent.
- FIG. 5 illustrates the precipitate is still present after the loading process with sodium sulfate liposomes but not with ammonium sulfate liposomes.
- Liposomes to be used for remote loading are formed in an ionic solution that is intended to complex the loaded drug as a salt. Trapping agents can form complexes with loaded drugs and the stability of this complex is one factor that dictates liposome drug loading ability, stability and drug release rates. Comparison of different liposome trapping agents was made by evaluating the efficiency of carfilzomib loading.
- Mellitic acid (MA) was dissolved in water and titrated with diethylamine to a final pH of 5.5 and concentration of 83 mM (500 mequivilents of anion/L).
- Ammonium sulfate was prepared by dissolving ammonium sulfate solid to a final concentration of 250 mM (500 mequivilents of anion/L) no pH adjustment was made to yield a final pH of 5.6.
- NDS Napthelenedisulfonic acid
- the liposomal carfilzomib samples were dialyzed in dialysis tubing having a molecular weight cut off of 12,000-14,000. The samples are dialyzed against 5 mM HEPES, 10% sucrose pH 6.5 (stirring at 4 °C) at volume that is 100 fold greater than the sample volume. The dialysate was changed after 2 h then 2 more times after 12 h each. The carfilzomib liposomes were again analyzed for drug and lipid concentration as described above.
- the invention described here enables remote loading of carfilzomib from an insoluble precipitate into liposomes can be accomplished with various using the electrochemical gradient generated by various trapping agents including mellitic acid, ammonium sulfate and napthelene disulfononic acid.
- the efficiency of carfilzomib remote loading into liposomes at 100 g drug/mol of HSPC lipid for the drug which was added as the solid powder was 3.88% ⁇ 0.053% and 3.47% ⁇ 0.030% when heated to 65 °C for 30 and 120 min respectively.
- the efficiency of loading the drug as a 10 mg/mL DMSO solution was 97.0% ⁇ 2.38% when the drug/DMSO was added quickly and 96.3% ⁇ 1.09% when the drug/DMSO was added in 5 increments over 1 min to a liposome solution while vortexing.
- the drug/liposome mixture that results from the slow drug addition is clearer than the drug/liposome mixture that results from rapid addition of the drug.
- both solutions have no visible precipitate (or centrifugal precipitate at 10,000 rpm for 5 min) after heating to 65 °C for 30 min, which is a result of all of the drug being loaded into the liposomes regardless of the precipitate formed upon addition of the drug (FIG. 4).
- T m phase transition temperature
- An alternative to heating is to use lipids that are fluid phase at room temperature. The disadvantage of these lipids is that they are unstable in circulation and result in rapid drug release.
- Sterol modified lipids incorporate a novel lipid construction where cholesterol (sterol) is covalently attached to the phosphate headgroup.
- Sterol modified lipids have proven to render the sterol non-exchangable from the lipid bilayer in circulation. Sterol modified lipids are also fluid phase at room temperature, making them ideal for room temperature loading of drugs into liposomes that are to be used for in vivo delivery of therapeutics.
- the loading of carfilzomib into liposomes at room temperature was performed by using two liposome formulations composed of a molar ratio of 95 PChemsPC / 5 PEG-DSPE and another with a molar ratio of 3 POPC/2 Chol/0.15 PEG-DSPE each containing 250 mM ammonium sulfate as the trapping agent.
- the liposomes were prepared using the procedure, drug/liposome ratio, buffers ad pH as described in Example 1.
- the liposomes were stirred at room temperature (20 °C) and the carfilzomib was added as a 10 mg/mL DMSO solution in 5 increments over 1 min to result in a cloudy solution.
- the liposome/drug mixture was stirred at room temperature for a total of 30 min to yield a clear solution with the same appearance as the liposome solution before the drug was added.
- Liposome loading of drug from a precipitate into liposomes is evidenced by the resulting drug to lipid ratio and clarifying of the solution as the drug precipitate transfers into the liposome.
- Liposomes containing 250 mM ammonium sulfate as trapping agent and 250 mM sodium sulfate as control liposomes which would not remote load drug were prepared and loaded using the procedure described in Example 1 except a disposable polystyrene cuvette was used as the reaction vessel. The scattering of light at 600 nm was measured with a UV/vis spectrophotometer during the loading process.
- the sodium sulfate liposomes do not show any clarification of the precipitate during the loading procedure indication that the drug is not remote loading into the liposomes, (see FIG. 5).
- the ammonium sulfate liposomes efficiently load the drug resulting in clarification of the solution within 15 min.
- Liposomes were loaded with carfilzomib as described in Example 1 and were purified into deionized water. The sample was divided into two aliquots. To the first aliquot, concentrated Hepes pH 7.4 and NaCl was added so that the final concentration was 5mM Hepes, 145 mM NaCl (HBS). To the second aliquot, concentrated ammonium sulfate was added so that the final concentration was 250 mM. No obvious physical changes were initially observed. The samples were then heated at 65 °C for 30 min.
- the drug released using the reverse gradient is 6.5-fold greater than the drug released from the control with no reverse gradient (Table 2).
- HPLC chromatogram of the released drug was identical to the starting material indicating that no degradation of carfilzomib had taken place (FIG. 7).
- HPLC retention time for the stock solution of carfilzomib was 12.15 min and the retention time for the carfilzomib that was released from the remote loaded liposome was 12.27 min, as shown in FIG. 6.
- Carfilzomib was released from the liposome using a reverse gradient to yield the original molecule as indicated by HPLC analysis.
- Ammonium sulfate containing liposomes were diluted in 50 mM citric acid sucrose (10% wt/wt) buffer pH 4.0 to 1 mM phospholipid.
- Various amounts of DMSO were added so that when 200 ⁇ g drug was added from a lOmg/mL carfilzomib solution in DMSO the final DMSO concentration ranged from 1-10% v/v.
- DMSO had a dramatic effect on the ability of carfilzomib to remote load into liposomes. When absent, there is practically no loading. At concentrations 1% and above the loading efficiency ranges from 74-94%, with higher efficiencies observed at higher DMSO concentrations (FIG. 7). It should be noted that drug precipitates were observed in all samples before loading commenced, suggesting that the concentrations of DMSO used here are below the minimum concentration required to effectively solubilize carfilzomib at the drug concentration used (0.2 mg/mL).
- carfilzomib is solubilized in DMSO before diluting in liposome buffer solution prior to loading. It then immediately precipitates before remote loading.
- This study is designed to determine the DMSO concentration that is required to effectively solubilize carfilzomib at room temperature and at the temperature required for liposome loading into liposomes composed of high Tm lipids (65°C).
- Carfilzomib was added from a stock 10 mg/mL solution in DMSO to 1 mL of a citric acid/DMSO mixture so that the composition of DMSO was 2%, 25%, 50%, 75% and 100%. The final drug concentration was 0.2 mg/mL.
- the solutions were prepared and measured for optical density at 600 nm. The optical density at 600 nm is a good measure of how turbid or how much scattering material (such as drug precipitates) are in a solution, generally, the more precipitates the higher the absorbance. From FIG. 8 is apparent that at DMSO concentrations below 50% vol/vol (25°C) and 25% vol/vol (65°C) the drug remains in a precipitated form. Only when the concentration of DMSO is increased does it become effectively solubilized at this concentration of 0.2 mg/mL.
- Example 9 evaluates the effect of the time between the formation of the drug precipitate and the time it is loaded into liposomes.
- Liposomes were prepared from the same composition and methods as described in Example 1.
- Carfilzomib was dissolved in DMSO at a concentration of 10 mg/mL and we added to a final concentration of 2% (v/v) to 50 mM citrate, 10% sucrose at pH 3.5 containing no liposomes. Upon addition of the drug to the citrate buffer a precipitate was formed. The liposomes for loading were added to the solution containing drug precipitate either immediately after formation, after a 1 h delay or after a 12 h delay and then the precipitate was loaded into the liposomes using the loading conditions described in Example 1.
- Liposomes were prepared from the same composition and methods as described in Comparison of Trapping Agents except the concentration of ammonium sulfate internal trapping agent was either 250 mM or 500 mM.
- Carfilzomib was dissolved in DMSO at a concentration of 10 mg/mL.
- the carfilzomib was introduced to the liposomes at carfilzomib to HSPC ratios of 91.8, 167, 251, 338 and 433, g drug/mol HSPC for the liposomes having 250 mM ammonium sulfate as the trapping agent and 451, 546, 639, and 759 g drug/mol HSPC for the liposomes having 500 mM ammonium sulfate as the trapping agent.
- the liposomes were diluted with 50 mM citrate, 10% sucrose pH 4.0 to increase the volume to a point where after addition of the drug the final DMSO concentration is 10%.
- the carfilzomib/DMSO was added to the diluted liposomes, which were mixed at room temperature then transferred to a 65° C bath and swirled every 30 s for the first 3 min and then swirled every 5 min over a total heating time of 30 min. All samples were very cloudy when the drug was added and all became clear (same as liposomes with no drug added) after 15 min. After heating for 30 min all samples were placed on ice for 15 min. The loaded liposomes were purified and analyzed as described in Example 1.
- the resulting drug payload increases as the drug to liposome input lipid ratios is increased in the loading solution.
- the efficiency is greatest at the lowest input ratio used for each different concentration of ammonium sulfate trapping agent.
- carfilzomib can be loaded into liposomes from an insoluble precipitate up to a final drug payload of 469 ⁇ 4.9 g drug/mol HSPC (drug/carrier total lipid weight ratio of 0.4) at an efficiency of 61.7 ⁇ 1.2%.
- the liposomes were prepared by using the same compositions and procedure as described in Carfilzomib Liposome Entrapment by Remote Loading with the following exception that 50mM triethylammonium sulfate was used as the trapping agent.
- Triethylammonium Sulfate was prepared by titrating 1 M sulfuric acid with triethylamine to a final pH of 7.3 and sulfate concentration of 500 mM.
- Carfilzomib was dissolved in DMSO at a concentration of 10 mg/mL.
- the carfilzomib was introduced to the liposomes at carfilzomib to HSPC ratios of 650 g drug/mol HSPC.
- the liposomes were diluted with 50 mM citrate, 10% sucrose pH 4.0 to increase the volume to a point where after addition of the drug the final DMSO concentration is 10%.
- the carfilzomib/DMSO was added to the diluted liposomes, which were mixed at room temperature then transferred to a 65° C bath and swirled every 30 s for the first 3 min and then swirled every 5 min.
- FIG. 12 illustrates the time dependence on the liposome loading, which begins quickly by 10 min. The greatest payload achieved was 440 ⁇ 12.6 g drug/mol HSPC (efficiency of 65.9 ⁇ 1.98%) was achieved at 30 min.
- Another drug, aripiprazole is formulated with sulfobutyl cyclodextran (SBCD) and is used to treat bipolar disorders and schizophrenia (Abilify, Pfizer).
- SBCD sulfobutyl cyclodextran
- the drug is very insoluble in water and when added to a liposome suspension, fine precipitates are immediately observed.
- Liposomes (HSPC/Chol/PEG-DSPE 3/2/0.15 mol/mol/mol) containing 250mM ammonium sulfate or 250mM sodium sulfate were diluted in 1 mL of 50mM citric acid, 10% (wt/wt) sucrose, pH 4.0 to a concentration of 6mM phospholipid.
- 0.3mg of aripiprazole was added from a stock solution of 15 mg/mL in DMSO, so that the final DMSO concentration was 2% (v/v). Fine precipitates were immediately observed after the drug was added to both liposome samples. The samples were heated at 65°C for 30 min, the cooled on ice.
- the samples were filtered through a 0.2um polyethersulfone syringe filter to remove any drug precipitates, followed by purification on a Sephadex G25 column equilibrated with HBS, pH 6.5 to remove any soluble extraliposome drug.
- the turbid fraction was collected and analyzed for lipid and drug as described above.
- the liposomes containing ammonium sulfate were found to load approximately 85% of the drug, while the loading into sodium sulfate liposomes was less than 2%, with about a 50-fold increase in loading attributable to the ability of ammonium sulfate liposomes to facilitate remote loading (Table 5).
- Ariprazole when introduced to the liposome solution in the form of a SBCD complex (from the pharmaceutical product Abilify) gave a loading efficiency of 68% under the same concentration and loading conditions (FIG. 14).
- This Example describes a technique for remote loading poorly soluble drugs into liposomes that begins with dissolving the drug in a solubilizing agent that initially forms drug precipitates when added to an aqueous solution of liposomes. After some incubation time the drug enters the liposome in response to an electrochemical gradient, accumulating in the liposome core.
- Solvents that may be used include but not limited to dimethylsulfoxide, dioxane, tetrahydrofuran, dimethylformamide, acetonitrile, dimethylacetamide, sulfolane, gamma butyrolactone, pyrrolidones, l-methyl-2-pyrrolidinone, methylpyrroline, ethylene glycol monomethyl ether, diethylene glycol monomethyl ether, polyethylene glycol.
- Aripiprazole was dissolved in a range of solvents indicated below at 4mg/mL.
- Liposomes composed of HSPC/Chol/PEG-DSPE (3/2/0.15 mol/mol/mol) that were prepared in 250mM ammonium sulfate were used and diluted to 6mM in Hepes buffered sucrose 10% (wt/wt) (HBSuc pH 6.5). 0.3 mg of drug was introduced by slow addition of each solvent while vortexing. The final solvent concentration was 7.5% for all samples. As controls, the drug was added from each solvent to the same volume of HBSuc pH 6.5 without the liposomes. The samples were heated at 65 °C for 30 min then cooled on ice. After reaching room temperature again, the samples were measured for absorbance at 600nm (Cary 100 Bio UV-Vis spectrometer) and the values are displayed below (FIG. 15).
- Liposomes are prepared as described in Example 1 but in this case the liposomes are extruded in a solution of 120 mM calcium acetate at pH 8. The acetate gradient is formed by exchangeing the external media for 120 mM sodium sulfate at pH 6.0. Deferasirox is dissolved in DMSO at a concentration of 10 mg/ml and added to the liposome suspension where it forms a precipitate. The precipitate is loaded into the liposomes by heating to 65 °C for 1 h and purification and analysis is performed as described in Example 1.
- Deferasirox forms a precipitate when diluted from a 10 mg/ml DMSO stock to a concentration of 1 mg/ml in the liposome loading suspension due to its poor water solubility (-0.038 mg/mL).
- the insoluble deferasirox precipitate is loaded into the liposomes using a calcium acetate gradient at an efficiency at least 5 -fold greater than it is loaded into control liposomes which contain sodium sulfate and no acetate gradient.
- Remote loading an insoluble precipitate of deferasirox into the liposome provides an example of the use of an acetate gradient to remote load a carboxylate drug from a precipitate.
- the drug being loaded is a chelating agent, in particular an iron chelating agent.
- the 5-fold greater loading into the liposomes having an acetate gradient over control liposomes indicates that the majority of the deferasirox is remote loaded rather than intercalated in the lipid bilayer.
- One goal of liposomal delivery of carfilzomib is to protect the drug from degradation and elimination which required the drug to be retained within the liposome.
- One technique for evaluating the drug retention within the liposome, and thus the benefits obtained from liposome delivery, is to measure the pharmacokinetics of the drug in mice. Stable formulations with greater drug retention within the liposome will result in a higher concentration of non-metabolized drug in mouse plasma compared to less stable formulations or unencapsulated drug.
- 100 nm liposomes comprised of HSPC/Cholesterol/PEG-DSPE (60/40/5
- mol/mol/mol mol/mol/mol
- sphingomyelin/cholesterol/PEG-DSPE 55/45/2.8, mol/mol/mol
- the trapping agents used to remote load carfilzomib were triethylammonium dextran sulfate (1.0 M S0 4 ) or triethylammonium sucroseoctasulfate (1.0 M S0 4 ).
- the drug loaded liposomes were purified by tangential flow filtration with buffer exchange into HBS, pH 6.5.
- the liposomes were sterile filtered through 0.2 um polyethersulfone filters and assayed for carfilzomib and lipid content as described in Example 1.
- the drug-to-lipid ratio, drug concentration and loading efficiency were calculated and results shown in Table 6.
- ⁇ formulation #3 is the same as #2 except it was stored at 4 °C for 30 days before PK analysis
- mice were dosed by IV bolus injection through the tail vein at 5 mg/kg carfilzomib using 3 mice per formulation. At 4 h, the mice were sacrificed and plasma harvested by centrifugation of the blood. 0.1 mL of plasma was mixed with 0.2 mL methanol, mixed well and carfilzomib concentration measured by HPLC as described in Example 1. The results are shown in Table 6.
- the liposomes described above increased the plasma retention of carfilzomib 46-to-4735 fold more than a SBCD formulation, or 5-to-510 fold higher than published liposome formulations at 4 h post administration. (Chu et al 2012 AAPS Meeting, Poster T2082).
- Liposomes were prepared using the extrusion and purification method described in Example 1.
- the lipid composition was HSPC/Cholesterol (3/0.5, mol/mol) or
- POPC/cholesterol (3/0.5, mol/mol).
- the trapping agent consisted of calcium acetate or sodium sulfate each at a concentration of 120 mM.
- a solution of DFX in DMSO at 20 mg/mL was added to the liposome solution slowly over 30 seconds while vortexing to produce a drug precipitate in the liposome solution.
- the target drug to phospholipid ratio was 100 g DFX/mol phospholipid.
- the solution was heated for 30 min (at 45 °C for POPC liposomes and 65 °C for HSPC liposomes) and then cooled on ice.
- the liposomes containing sodium sulfate resulted in 3.3% loading efficiency, which indicates that the loading of DFX into calcium acetate liposomes is not passive but can be described as remote loading.
- the DFX loading results are shown in Table 7 (FIG. 16).
- Liposomes were prepared using the extrusion and purification method described in Example 1.
- the lipid composition was POPC/cholesterol (3/0.5, mol/mol).
- the trapping agent consisted of calcium acetate 120 mM, 250 mM or 500 mM.
- a solution of DFX in DMSO at 20 mg/mL was added to the liposome solution slowly over 30 seconds while vortexing to produce a drug precipitate in the liposome solution.
- the target drug to phospholipid ratio was 100, 200 or 300 g DFX/mol phospholipid. The solution was heated for 30 min at 45 °C and then cooled on ice.
- the drug payload capacity of DFX when remote loaded into liposomes can be substantially increased by increasing the concentration of the trapping agent concentration inside the liposome.
- This example demonstrates the dependence of loading capacity on calcium acetate trapping agent concentration.
- This example also demonstrates DFX liposome loading can have an optimum drug to lipid ratio where the efficiency and drug load are both greatest. The achieved drug to lipid ratio allows for the DFX to be administered to an animal using a tolerated dose of lipid.
- Liposomes were prepared using the extrusion and purification method described in Example 1.
- the lipid composition was POPC/cholesterol (3/0.5, mol/mol).
- the trapping agent consisted of calcium acetate, magnesium acetate or zinc acetate at 120 mM.
- a solution of DFX in DMSO at 20 mg/mL was added to the liposome solution slowly over 30 seconds while vortexing to produce a drug precipitate in the liposome solution.
- the target drug to phospholipid ratio was 100, 150 or 200 g DFX/mol phospholipid. The solution was heated for 30 min at 45 °C and then cooled on ice.
- the DFX forms a precipitate before loading.
- the solutions containing liposomes with calcium acetate and magnesium acetate became much less turbid than the liposomes containing zinc acetate as the trapping agent.
- the maximum drug load was highest for the liposomes containing magnesium the second highest for the liposomes containing calcium acetate and the liposomes containing zinc acetate resulted in the lowest drug payload.
- the efficiency of loading for a target of 100 g DFX/mol phospholipid was 5.3 ⁇ 0.07% but the efficiency using calcium acetate and magnesium acetate were 97.6 ⁇ 0.41% and 99.2 ⁇ 2.42% respectively.
- the results are shown in FIG. 18.
- the drug payload capacity of DFX when remote loaded into liposomes can be dependent on the particular metal salt of acetate used for remote loading. This example demonstrates that magnesium acetate is a better trapping agent for DFX than calcium acetate or zinc acetate.
- Liposomes were prepared with a lipid composition of HSPC/DSPG/Chol/PEG-DSPE in the ratio 2/0.6/2/0.3 containing 1.0 M (S0 4 ) TEA dextran sulfate.
- the liposomes were separated form the non-entrapped TEA dextran sulfate by anion exchange and then by dialysis against 5mM Hepes buffered 10% (wt/wt) sucrose pH 6.5.
- the liposomes were exchanged into 0.01 N HCL, 10% sucrose pH 2.0 before drug loading.
- Amphotericin B was dissolved in DMSO at 10 mg/ml.
- the DMSO amphotericin B solution was added dropwise to the liposomes at room temperature while the liposomes suspension was rapidly mixed on a vortex mixer.
- the concentration of the liposomal lipid was 5 umol (phospholipid)/mL and 0.1 mL of the amphotericin B solution was added per mL of liposomes so that the final amphotericin B concentration was about 1.0 mg/ml AmB and the final DMSO concentration was about 10% (V/V).
- AmB/PL ratios were tested, e.g., 200, 400, 800 g/mol.
- Amphotericin B was remote loaded into liposomes at 96% efficiency at a 200 g drug/mole lipid, at the input ratio of 400 g drug/mole of lipid the drug was about 90% encapsulated to provide a purified preparation of 360 g amphotericin B/mole lipid. At 800 g drug/mole lipid, amphotericin B was about 70% encapsulated, to provide 560 g amphotericin B/mole lipid. All of these values are substantially greater than the approximate value of 120 g amphotericin B / mole lipid that is contained in the drug product Ambisome®. The final liposome preparation was readily concentrated to a 10 mg/mL amphotericin B concentration in the 5 mM Hepes, 144 mM NaCl, pH 7.4 buffer.
- 2'-succinylcarbazitaxel is synthesized by reacting a solution of 0.050 g (0.060 mmol) of carbazitaxel and 0.090 g (0.076 mmol) of succinyl anhydride for three hours at room temperature in 3 mL of pyridine. The reaction mixture is evaporated to dryness in vacuo. The residue is treated with 10 mL of water, stirred for 20 min, and filtered. The precipitate is dissolved in acetone, water is slowly added, and the tiny crystals are collected. The crystals are recrystalled from chloroform/benzene to yield the product,
- the 2' succinyl ester of carbazitaxel was converted into a morpholin-4-ylethyl amide by reacting the 2' glutaryl ester of carbazitaxel in the presence of CDI with acetonitrile as a solvent with 2-(morpholin-4-yl)ethanamine.
- CDI acetonitrile
- paclitaxel and docetaxel are prepared in a similar manner to the above synthesis to provide sparingly soluble taxane derivatives whose solubility can be adjusted by altering the pH of the liposome solution in which the aprotic solution of the derivatives are added.
- Liposomes were prepared using the extrusion and purification method described in Example 1.
- the lipid composition was POPC/cholesterol (3/0.5, mol/mol).
- the trapping agent consisted of zinc acetate or magnesium acetate at 120 mM.
- a solution of either unmodify carbazitaxel or 2'succinylcarbazitaxel in DMSO at 20 mg/mL was added to the liposome solution slowly over 30 seconds while vortexing to produce a drug precipitate in the liposome solution.
- the target drug to phospholipid ratio was 100 g/mole lipid for unmodified carbazitaxel and 100, 150 or 200 g for succinylcarbazitaxel/mol phospholipid.
- the solutions are heated for 30 min at 45 °C and then cooled on ice. A sample was removed to determine the input drug to lipid ratio and the remaining solution was spun in a centrifuge at 12,000 RPM for 5 minutes to pellet any unloaded drug. The supernatant was further purified from unloaded drug using a Sephadex G25 size exclusion column eluted with 5 mM HEPES, 145 mM NaCl at pH 6.5. The purified liposomes were analyzed for drug and lipid content by HPLC as described in Example 16.
- both the carbazitaxel and 2'succinylcarbazitaxel formed a white precipitate before loading.
- the white precipitate of the unmodified carbazitaxel solutions containing liposomes was unchanged.
- the 2'-succinylcabazitaxel solution with zinc acetate or magnesium acetate liposomes the turbidity was substantially less.
- the maximum 2'succinylcarbazitaxel load was highest for the liposomes containing magnesium acetate and second highest for the liposomes containing zinc acetate.
- the loading efficacy was greater than 85% in loading the 2'succinylcabazitaxel.
- the efficiency of loading unmodified carbazitaxel added at 100 g carbazitaxel/mol phospholipid was very low in both the calcium acetate and magnesium acetate liposomes.
- liposomes were prepared with a lipid composition of HSPC/DSPG/Chol/PEG-DSPE in the ratio 2/0.6/2/0.3 containing 1.0 M (S0 4 ) TEA dextran sulfate.
- the liposomes were separated form the non-entrapped TEA dextran sulfate by anion exchange and then by dialysis against 5mM Hepes buffered 10% (wt/wt) sucrose, pH 6.5. 2' morpholine-4-ylethyl amide of
- succinylcabazitaxel was dissolved in DMSO at 10 mg/mL.
- succinylcabazitaxel solution was added dropwise to the liposomes at room temperature while the liposomes suspension was rapidly mixed on a vortex mixer.
- the concentration of the liposomal lipid was 5 umol (phospholipid)/mL and 0.1 mL of the 2' morpholine-4-ylethyl amide of succinylcabazitaxel solution was added per mL of liposomes so that the final 2' morpholine-4-ylethyl amide of succinylcabazitaxel concentration was about 1.0 mg/ml and the final DMSO concentration was about 10% (V/V).
- succinylcabazitaxel compound The solutions were heated for 30 min at 45 °C and then cooled on ice. A sample was removed to determine the input drug to lipid ratio and the remaining solution is spun in a centrifuge at 12,000 RPM for 5 minutes to pellet any unloaded drug. The supernatant was further purified from unloaded drug using a Sephadex G25 size exclusion column eluted with 5 mM HEPES, 145 mM NaCl at pH 6.5. The purified liposomes were analyzed for drug and lipid content by HPLC as described in Example 16. Using a similar method for precipitate loading the 2' morpholine-propyl ester cabazitaxel (FIG. 19) can be precipitate loaded into liposomes containing the TEA-dextran sulfate gradient.
- FIG. 19 2' morpholine-propyl ester cabazitaxel
- the unmodified carbazitaxel formed a white turbid precipitate when added to the liposome suspension in a DMSO solution but the precipitate did not clear up upon heating.
- the encapsulation of cabazitaxel was less then 5% of the added drug.
- the 2' morpholine-4- ylethyl amide of succinylcabazitaxel and 2' morpholinopropyl derivatives of cabazitaxel (figure 19) formed a white turbid precipitate when added to the liposomes that cleared upon heating.
- the precipitate was loaded into TEA-dextran sulfate liposomes at greater than 90% of the added drug at the 200 and 400 g drug/ mole lipid ratios and greater than 70% at the 800 g drug/mole lipid.
- pH titratable taxane derivatives can be remote loaded into liposomes from a precipitate formed when the taxane derivative is added in an aprotic solvent to a preformed liposome containing remote loading agent where the concentration of the mobile ion species is greater on the inside than on the outside of the liposome.
- Taxanes modified to contain a carboxylate on the 2 ⁇ position can be loaded into liposomes that contain a divalent cation with a mobile anionic salt such as acetate.
- Taxanes modified at the 2'hydroxyl group to contain a titratable amine can be remote loaded in liposomes containing a mobile cation such as ammonium or triethylamine and an impermeable anion such as sulfate or dextran sulfate.
- a mobile cation such as ammonium or triethylamine
- an impermeable anion such as sulfate or dextran sulfate.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2962709A CA2962709C (en) | 2014-08-04 | 2015-08-04 | Remote loading of sparingly water-soluble drugs into lipid vesicles |
EP15829535.2A EP3177269A4 (en) | 2014-08-04 | 2015-08-04 | Remote loading of sparingly water-soluble drugs into lipid vesicles |
CN201580053705.2A CN106999419A (en) | 2014-08-04 | 2015-08-04 | Remote loading sparingly water-soluble medicine is to lipid film bubble |
AU2015301234A AU2015301234A1 (en) | 2014-08-04 | 2015-08-04 | Remote loading of sparingly water-soluble drugs into lipid vesicles |
US15/502,092 US10004759B2 (en) | 2014-08-04 | 2015-08-04 | Remote loading of sparingly water-soluble drugs into lipid vesicles |
ZA2017/02070A ZA201702070B (en) | 2014-08-04 | 2017-03-24 | Remote loading of sparingly water-soluble drugs into lipid vesicles |
US15/972,012 US20190105339A1 (en) | 2014-08-04 | 2018-05-04 | Remote loading of sparingly water-soluble drugs into lipid vesicles |
US16/726,624 US11583544B2 (en) | 2014-08-04 | 2019-12-24 | Remote loading of sparingly water-soluble drugs into lipid vesicles |
US18/170,704 US20230390317A1 (en) | 2014-08-04 | 2023-02-17 | Remote Loading of Sparingly Water-Soluble Drugs Into Lipid Vesicles |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462033073P | 2014-08-04 | 2014-08-04 | |
US62/033,073 | 2014-08-04 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/502,092 A-371-Of-International US10004759B2 (en) | 2014-08-04 | 2015-08-04 | Remote loading of sparingly water-soluble drugs into lipid vesicles |
US15/972,012 Continuation US20190105339A1 (en) | 2014-08-04 | 2018-05-04 | Remote loading of sparingly water-soluble drugs into lipid vesicles |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016022549A1 true WO2016022549A1 (en) | 2016-02-11 |
Family
ID=55264423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/043594 WO2016022549A1 (en) | 2014-08-04 | 2015-08-04 | Remote loading of sparingly water-soluble drugs into lipid vesicles |
Country Status (7)
Country | Link |
---|---|
US (4) | US10004759B2 (en) |
EP (1) | EP3177269A4 (en) |
CN (1) | CN106999419A (en) |
AU (1) | AU2015301234A1 (en) |
CA (1) | CA2962709C (en) |
WO (1) | WO2016022549A1 (en) |
ZA (1) | ZA201702070B (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108066312A (en) * | 2017-12-29 | 2018-05-25 | 山东裕欣药业有限公司 | A kind of Pa Boxini pharmaceutical compositions and preparation method thereof |
US10004759B2 (en) | 2014-08-04 | 2018-06-26 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into lipid vesicles |
CN110114068A (en) * | 2016-12-26 | 2019-08-09 | 富士胶片株式会社 | Lipid particle composition and medical composition |
WO2020081485A1 (en) * | 2018-10-17 | 2020-04-23 | Taiwan Liposome Co., Ltd. | Sustained-release pharmaceutical compositions comprising an immunomodulating agent and uses thereof |
TWI772664B (en) * | 2018-08-08 | 2022-08-01 | 台灣微脂體股份有限公司 | Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014121211A2 (en) * | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into liposomes |
US10220095B2 (en) | 2013-03-15 | 2019-03-05 | Taiwan Liposome Company, Ltd | Controlled drug release liposome compositions and methods thereof |
CN108853507A (en) * | 2017-05-11 | 2018-11-23 | 复旦大学 | A kind of antitumor synergism medicine composition and its preparation method and application |
CN112654345A (en) * | 2018-09-10 | 2021-04-13 | 台湾微脂体股份有限公司 | Sustained-release ophthalmic pharmaceutical composition and use thereof |
CN109260155B (en) * | 2018-11-05 | 2021-04-06 | 杭州高田生物医药有限公司 | Irinotecan liposome preparation and application thereof |
US20220211623A1 (en) * | 2019-05-14 | 2022-07-07 | Inspirmed Corp. | Inhalable sustained release composition of bronchodilator for use in treating pulmonary disease |
CN112336874B (en) * | 2019-08-08 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | Nanometer medicine carrier and its prepn and application |
CN114958347B (en) * | 2022-06-17 | 2023-08-01 | 中南林业科技大学 | Chemiluminescent probe, preparation method thereof and application thereof in detection of hydrazine hydrate |
CN115429793A (en) * | 2022-08-15 | 2022-12-06 | 复旦大学附属中山医院 | Application of compound in preparation of medicine for treating hepatocellular carcinoma |
WO2024067849A1 (en) * | 2022-09-30 | 2024-04-04 | 上海济煜医药科技有限公司 | Liposome pharmaceutical composition, preparation method therefor, and use thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3335134A (en) * | 1964-04-02 | 1967-08-08 | Sandoz Ag | Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones |
US20030068365A1 (en) * | 2001-10-05 | 2003-04-10 | Pichit Suvanprakorn | Compositions and methods for administration of active agents using liposome beads |
US20040126886A1 (en) * | 2000-09-25 | 2004-07-01 | Industrial Technology Research Institute | Liposome for incorporating large amounts of hydrophobic substances |
US20060039965A1 (en) * | 2001-04-11 | 2006-02-23 | Boch Ronald E | Drug delivery system for hydrophobic drugs |
US20090196918A1 (en) * | 2008-02-01 | 2009-08-06 | University Of Kentucky Research Foundation | Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions |
WO2012118376A1 (en) * | 2011-03-01 | 2012-09-07 | To-Bbb Holding B.V. | Advanced active liposomal loading of poorly water-soluble substances |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3932657A (en) | 1973-11-12 | 1976-01-13 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome encapsulation of chelating agents |
US4016290A (en) | 1973-11-12 | 1977-04-05 | The United States Of America As Represented By The United States Energy Research And Development Administration | Method of encapsulating polyaminopolycarboxylic acid chelating agents in liposomes |
US4310506A (en) | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
NZ201010A (en) | 1981-06-19 | 1986-02-21 | Ciba Geigy Ag | The treatment of inflammation diseases using desferrioxamine |
US5043166A (en) | 1987-01-09 | 1991-08-27 | Hadasit Medical Research, Inc. | Liposome/anthraquinone drug composition and method |
MX9203808A (en) | 1987-03-05 | 1992-07-01 | Liposome Co Inc | HIGH DRUG CONTENT FORMULATIONS: LIPID, FROM LIPOSOMIC-ANTINEOPLASTIC AGENTS. |
IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
ATE137403T1 (en) | 1989-03-31 | 1996-05-15 | Univ California | PREPARATION OF LIPOSOME AND LIPID COMPLEX COMPOSITIONS |
US5534241A (en) | 1993-07-23 | 1996-07-09 | Torchilin; Vladimir P. | Amphipathic polychelating compounds and methods of use |
DE4341472A1 (en) | 1993-12-02 | 1995-06-08 | Schering Ag | A method for increasing the stability of liposome suspensions containing hydrophilic drugs |
US5662929A (en) * | 1994-12-23 | 1997-09-02 | Universite De Montreal | Therapeutic liposomal formulation |
US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
AU5557796A (en) | 1995-04-18 | 1996-11-07 | Dehlinger, Peter J. | Liposome drug-loading method and composition |
US6447800B2 (en) | 1996-01-18 | 2002-09-10 | The University Of British Columbia | Method of loading preformed liposomes using ethanol |
US5837282A (en) | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
US5827532A (en) | 1997-01-31 | 1998-10-27 | The Reagents Of The University Of California | Method for loading lipsomes with ionizable phosphorylated hydrophobic compounds, pharmaceutical preparations and a method for administering the preparations |
US7112338B2 (en) * | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
DE69935435T2 (en) | 1998-08-12 | 2007-12-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Ammonium sulfate gradient prepared liposomal analgesic compositions |
US8029795B2 (en) | 1999-12-30 | 2011-10-04 | Gwathmey, Inc. | Targeted iron chelator delivery system |
AU2002334358B2 (en) | 2001-09-06 | 2008-02-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | A method for preparing liposome formulations with a predefined release profile |
US20050208119A1 (en) | 2004-03-18 | 2005-09-22 | Takemoto Arnold C | Encapsulated oral chelating preparations |
US20050208118A1 (en) | 2004-03-18 | 2005-09-22 | Takemoto Arnold C | Preparations of encapsulated bioavailable chelating agents for detoxifying humans and animals |
CN107811971B (en) | 2004-05-03 | 2021-10-29 | 益普生生物制药公司 | Liposomes for drug delivery |
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
EP1817005A1 (en) * | 2004-11-18 | 2007-08-15 | Celator Pharmaceuticals, Inc. | Method for loading multiple agents into delivery vehicles |
US20090028931A1 (en) | 2005-01-28 | 2009-01-29 | Bc Cancer Agency | Liposomal compositions for parenteral delivery of agents |
US20070014845A1 (en) | 2005-07-01 | 2007-01-18 | Yuanpeng Zhang | Liposomal delivery vehicle for hydrophobic drugs |
BRPI0615349A2 (en) | 2005-09-02 | 2011-05-17 | Neuraxo Biopharmaceuticals Gmbh | pharmaceutical composition comprising an iron chelator |
US20120021042A1 (en) | 2005-09-15 | 2012-01-26 | Steffen Panzner | Efficient Method For Loading Amphoteric Liposomes With Nucleic Acid Active Substances |
US20080107747A1 (en) | 2006-10-23 | 2008-05-08 | Roederer Joy E | Pain relief composition |
CA2697042A1 (en) | 2007-08-21 | 2009-02-26 | Alza Corporation | Liposome compositions for in vivo administration of boronic acid compounds |
US8481526B2 (en) | 2009-03-25 | 2013-07-09 | Bausch & Lomb Incorporated | Fluoroquinolone carboxylic acid molecular crystals |
US20120058178A1 (en) | 2009-03-30 | 2012-03-08 | Eisai R&D Management Co., Ltd. | Liposome Composition |
WO2011038073A1 (en) | 2009-09-23 | 2011-03-31 | Formatech, Inc. | Methods for the preparation of liposomes comprising docetaxel |
BR112012009660B8 (en) | 2009-10-26 | 2021-05-25 | Cspc Zhongqi Pharmaceutical Tech Shijiazhuang Co Ltd | liposome having internal water phase containing sulfobutyl ether cyclodextrin salt, its preparation process, its use and liposomal pharmaceutical preparation |
US20110178287A1 (en) | 2010-01-19 | 2011-07-21 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
WO2011092708A2 (en) | 2010-02-01 | 2011-08-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Liposomes comprising amphipathic drugs and method for their preparation |
WO2014121235A2 (en) | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
WO2014121211A2 (en) | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into liposomes |
CA2906794A1 (en) | 2013-03-14 | 2014-09-25 | Zoneone Pharma, Inc. | Pharmaceutical formulations of chelating agents as a metal removal treatment system |
PL2968146T3 (en) * | 2013-03-15 | 2020-06-29 | Taiwan Liposome Company, Ltd. | Controlled drug release liposome composition |
EP3177269A4 (en) | 2014-08-04 | 2018-02-28 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into lipid vesicles |
WO2016025559A1 (en) | 2014-08-13 | 2016-02-18 | Zoneone Pharma, Inc. | Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems |
WO2016025611A2 (en) | 2014-08-13 | 2016-02-18 | Zoneone Pharma, Inc. | Pharmaceutical formulations of chelating agents as a metal removal treatment system |
-
2015
- 2015-08-04 EP EP15829535.2A patent/EP3177269A4/en not_active Withdrawn
- 2015-08-04 US US15/502,092 patent/US10004759B2/en active Active
- 2015-08-04 WO PCT/US2015/043594 patent/WO2016022549A1/en active Application Filing
- 2015-08-04 CA CA2962709A patent/CA2962709C/en active Active
- 2015-08-04 AU AU2015301234A patent/AU2015301234A1/en not_active Abandoned
- 2015-08-04 CN CN201580053705.2A patent/CN106999419A/en active Pending
-
2017
- 2017-03-24 ZA ZA2017/02070A patent/ZA201702070B/en unknown
-
2018
- 2018-05-04 US US15/972,012 patent/US20190105339A1/en not_active Abandoned
-
2019
- 2019-12-24 US US16/726,624 patent/US11583544B2/en active Active
-
2023
- 2023-02-17 US US18/170,704 patent/US20230390317A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3335134A (en) * | 1964-04-02 | 1967-08-08 | Sandoz Ag | Certain 3, 4-dihydrofluoreno[1, 9a, 9-e, f]1, 4-diazepin-3(2h)-ones |
US20040126886A1 (en) * | 2000-09-25 | 2004-07-01 | Industrial Technology Research Institute | Liposome for incorporating large amounts of hydrophobic substances |
US20060039965A1 (en) * | 2001-04-11 | 2006-02-23 | Boch Ronald E | Drug delivery system for hydrophobic drugs |
US20030068365A1 (en) * | 2001-10-05 | 2003-04-10 | Pichit Suvanprakorn | Compositions and methods for administration of active agents using liposome beads |
US20090196918A1 (en) * | 2008-02-01 | 2009-08-06 | University Of Kentucky Research Foundation | Liposomal formulations of hydrophobic lactone drugs in the presence of metal ions |
WO2012118376A1 (en) * | 2011-03-01 | 2012-09-07 | To-Bbb Holding B.V. | Advanced active liposomal loading of poorly water-soluble substances |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10004759B2 (en) | 2014-08-04 | 2018-06-26 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into lipid vesicles |
US11583544B2 (en) | 2014-08-04 | 2023-02-21 | Celator Pharmaceuticals, Inc. | Remote loading of sparingly water-soluble drugs into lipid vesicles |
CN110114068A (en) * | 2016-12-26 | 2019-08-09 | 富士胶片株式会社 | Lipid particle composition and medical composition |
EP3560492A4 (en) * | 2016-12-26 | 2020-06-17 | Fujifilm Corporation | Lipid particle composition and pharmaceutical composition |
US11154534B2 (en) | 2016-12-26 | 2021-10-26 | Fujifilm Corporation | Lipid particle composition and pharmaceutical composition |
CN108066312A (en) * | 2017-12-29 | 2018-05-25 | 山东裕欣药业有限公司 | A kind of Pa Boxini pharmaceutical compositions and preparation method thereof |
TWI772664B (en) * | 2018-08-08 | 2022-08-01 | 台灣微脂體股份有限公司 | Sustained-release pharmaceutical compositions comprising an antipsychotic drug and uses thereof |
WO2020081485A1 (en) * | 2018-10-17 | 2020-04-23 | Taiwan Liposome Co., Ltd. | Sustained-release pharmaceutical compositions comprising an immunomodulating agent and uses thereof |
US20210393524A1 (en) * | 2018-10-17 | 2021-12-23 | Taiwan Liposome Co., Ltd. | Sustained-release pharmaceutical compositions comprising an immunomodulating agent and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CA2962709C (en) | 2023-09-19 |
US10004759B2 (en) | 2018-06-26 |
CN106999419A (en) | 2017-08-01 |
EP3177269A4 (en) | 2018-02-28 |
EP3177269A1 (en) | 2017-06-14 |
CA2962709A1 (en) | 2016-02-11 |
US20230390317A1 (en) | 2023-12-07 |
US20170224715A1 (en) | 2017-08-10 |
US11583544B2 (en) | 2023-02-21 |
US20190105339A1 (en) | 2019-04-11 |
AU2015301234A1 (en) | 2017-06-15 |
ZA201702070B (en) | 2023-03-29 |
US20210008091A1 (en) | 2021-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10722467B2 (en) | Remote loading of sparingly water-soluble drugs into liposomes | |
US11583544B2 (en) | Remote loading of sparingly water-soluble drugs into lipid vesicles | |
US20140220112A1 (en) | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes | |
EP2680820B1 (en) | Advanced active liposomal loading of poorly water-soluble substances | |
WO2024081910A1 (en) | Liposome compositions for delivery of compounds and methods thereof | |
TW202320803A (en) | Methods for preparing liposomal formulations | |
AU2022312484A1 (en) | Liposomal formulations of bcl inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15829535 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15502092 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2015829535 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015829535 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2962709 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2015301234 Country of ref document: AU Date of ref document: 20150804 Kind code of ref document: A |